JBIO Jade Biosciences, Inc.
Price Chart
Executive Summary
Jade Biosciences filed an S-3 resale registration for up to 39.5M shares held by selling stockholders (57.9% of outstanding), including entities affiliated with Fairmount, Fidelity, and RA Capital. The company will receive no proceeds. This filing coincides with a Q1 2026 earnings miss (EPS -$0.57 vs -$0.52 consensus) and widening net loss ($40.4M). The massive potential overhang creates significant downward pressure on the stock.
Actionable Insight
The massive resale registration (57.9% overhang) combined with a Q1 earnings miss creates strong near-term selling pressure. Monitor for actual sales by insiders; the registration becomes effective shortly. Consider short-term bearish bias until the overhang clears or a substantial portion is sold.
Key Facts
- Registers 39,542,339 shares for resale by selling stockholders, representing ~57.9% of shares outstanding as of March 15, 2026
- Company will not receive any proceeds from the resale; only nominal exercise proceeds from pre-funded warrants
- Q1 2026 EPS of -$0.57 missed consensus of -$0.52 by 9.6%; net loss widened to $40.4M from $38.2M YoY
- R&D spend increased 80% YoY to $36.1M; cash burn continues ($311M vs $336M in Dec 2025)
- Large insider selling overhang from PIPE investors including Fairmount (22.97M shares), Fidelity, RA Capital, Janus, Baker Bros
Financial Impact
Up to $489.7M in shares (at $23.57 per share) could be sold by selling stockholders; no proceeds to company
Risk Factors
- Significant stock price decline from actual or perceived selling by large holders
- Widening losses and cash burn without near-term revenue catalysts
- Further dilution if additional equity raises are needed
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-212443 |
| Document: d149521dexfilingfees.htm | 0001193125-26-212443 |
| Document: d149521dex51.htm | 0001193125-26-212443 |
| Document: d149521dex231.htm | 0001193125-26-212443 |
| Document: 0001193125-26-212443-index-headers.html | 0001193125-26-212443 |
| Document: 0001193125-26-212443-index.html | 0001193125-26-212443 |
| Document: 0001193125-26-212443.txt | 0001193125-26-212443 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
Press Release
| $16.91 awaiting T+1 | awaiting T+1 | — | $14.98 (+11.41%) |
|
Jun 4, 2026
5d ago
|
8-K
| $17.52 awaiting T+1 | awaiting T+1 | — | $14.98 (+14.50%) |
|
Jun 4, 2026
5d ago
|
424B5
| $17.52 awaiting T+1 | awaiting T+1 | — | $14.98 (+14.50%) |
|
Jun 4, 2026
6d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.91% | $14.98 (+15.56%) |
|
Jun 3, 2026
6d ago
|
424B5
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $14.98 (+15.56%) |
|
Jun 3, 2026
6d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $14.98 (+15.56%) |
|
Jun 1, 2026
8d ago
|
8-K
| $18.59 $17.75 | ▼ −4.52% | ▼ −4.66% | $14.98 (−19.42%) |
|
May 26, 2026
14d ago
|
Press Release
| $21.50 $20.84 | ▼ −3.07% | ▼ −3.62% | $14.98 (−30.33%) |
|
May 18, 2026
23d ago
|
EFFECT
| $22.01 $21.88 | ▲ +0.59% | ▼ −0.06% | $14.98 (+31.94%) |
|
May 7, 2026
4w ago
|
S-3
| $25.81 $24.86 | ▲ +3.68% | ▲ +3.91% | $14.98 (+41.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access